Dividend On Watch: Jan 12, 2017 is the day GlaxoSmithKline PLC (NYSE:GSK) promises dividends of $0.46. Here’s what they have to say.

Dividend On Watch: Jan 12, 2017 is the day GlaxoSmithKline PLC (NYSE:GSK) promises dividends of $0.46. Here's what they have to say.

GlaxoSmithKline PLC (NYSE:GSK) is expected to pay $0.46 on Jan 12, 2017. The indicated annual dividend is $1.84. Shareholders owning the stock before Nov 2, 2016 will be eligible to receive the payout. Based on GlaxoSmithKline PLC’s current price of $40.01, the dividend is 1.15%. This dividend’s record date is Nov 4, 2016 and the announcement date is Oct 26, 2016. The stock decreased 0.32% or $0.13 during the last trading session, hitting $40.01. GlaxoSmithKline plc (ADR) (NYSE:GSK) has declined 1.70% since March 30, 2016 and is downtrending. It has underperformed by 4.71% the S&P500.

GlaxoSmithKline plc is a healthcare company. The company has a market cap of $95.81 billion. The Firm is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. It has a 272.53 P/E ratio. The Company’s divisions include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare.

GlaxoSmithKline plc (ADR) (NYSE:GSK) Ratings Coverage

Out of 11 analysts covering GlaxoSmithKline (NYSE:GSK), 6 rate it a “Buy”, 1 “Sell”, while 4 “Hold”. This means 55% are positive. GlaxoSmithKline has been the topic of 16 analyst reports since September 8, 2015 according to StockzIntelligence Inc. The stock has “Buy” rating given by Jefferies on Thursday, July 14. The stock of GlaxoSmithKline plc (ADR) (NYSE:GSK) earned “Buy” rating by Investec on Thursday, October 20. The company was downgraded on Wednesday, September 14 by BNP Paribas. The firm earned “Buy” rating on Wednesday, January 27 by Bryan Garnier & Cie. Argus Research maintained GlaxoSmithKline plc (ADR) (NYSE:GSK) rating on Friday, August 12. Argus Research has “Buy” rating and $50 price target. On Friday, February 26 the stock rating was initiated by Cantor Fitzgerald with “Hold”. On Monday, December 7 the stock rating was maintained by Argus Research with “Buy”. Bank of America upgraded the stock to “Neutral” rating in Tuesday, September 8 report. The firm has “Neutral” rating by Credit Suisse given on Tuesday, October 20. The company was initiated on Friday, September 23 by Piperjaffray.

More news for GlaxoSmithKline plc (ADR) (NYSE:GSK) were recently published by: Businessfinancenews.com, which released: “GlaxoSmithKline plc (ADR) Earning Release; Here’s What to Expect” on July 26, 2016. Investorplace.com‘s article titled: “GlaxoSmithKline plc (ADR) (GSK) Seeks FDA Approval for New Shingles Vaccine” and published on October 24, 2016 is yet another important article.

GSK Company Profile

GlaxoSmithKline plc (GSK), incorporated on December 6, 1999, is a healthcare company. The Firm is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. GSK’s principal pharmaceutical products include medicines in various therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, vaccines and human immunodeficiency virus (HIV). The Company’s divisions include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags:

Related posts

Leave a Comment